Successful treatment with Protein C of febrile neutropenia in pediatric patients during cancer therapy.
Febrile Neutropenia (FN) is a complication of chemotherapy in childhood cancer and at the same time secondary deficit of Protein C (PC) is often present during sepsis in children with cancer. In this study we have compared the clinical outcome of two different groups. At the onset of FN during chemotherapy the first group (patients with a secondary deficit of PC) received Protein C Concentrate (PCC) replacement while the other group without PC deficiency received only symptomatic therapies. We report that PC replacement could shorten duration of FN and improve the clinical outcome. The administration of PCC was safe and without any complications.
Giordano
Paola
P
Department of Biomedicine of Development Age, University of Bari, Bari, Italy. giordano@bioetaev.uniba.it
Cecinati
Valerio
V
Delvecchio
Giovanni Carlo
GC
Arcamone
Giampaolo
G
De Leonardis
Francesco
F
Grassi
Massimo
M
Brescia
Letizia Pomponia
LP
Santoro
Nicola
N
De Mattia
Domenico
D
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy*; D011486:Protein C / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011486:Protein C